Dear Sirs,

Recently reported commentaries [1,2] have raised the question how much experimental settings employed in complementary and alternative medicine fit to the accepted rules of reliability and best performance that are required for a good scientific research; in this context, I firmly believe that biases are thoroughly to be faced during any investigation. Alcohol used in experiments reported in [3,4] is an example. According to the Authors [2-4] diluted doses of *Gelsemium sempervirens* did not provoke any sedation side-effect [2]. However, as each dose used in experimental settings, contained 0.3% ethanol and as each mouse underwent i.p. injections for 9 days [3] or 7-8 days [4], a simple calculation allows to estimate that each subject received throughout the indicated period a total amount of 6.00-7.00 mg ethanol, considering an administration of 1.0 μl/injection and EtOH density = 0.789 g/cm³ [3,4]. Recent reported evidence in rats suggested that this dose of alcohol may result in possible sedation, though injected in different times. In rats a dose of 0.25 g/kg EtOH has been shown to be the lowest dose able to decrease significantly locomotion in these rodents [5]. If one considers 500 g the mean body weight of a male subject, this dose should correspond to 125 mg of alcohol; a male mouse is about 1/25 of a male rat, so a mouse receiving about 5 mg of alcohol, might undergo comparable sedation effects. The experimental setting planned and performed by some Authors used ethanol in each tested sample, including controls: this should assure that sedation would be carried throughout the analysis, without influencing the net outcome of the experiment. Bias arises because ethanol is a pharmacological compound as like as gelsemine or buspirone [3,4]. Rodents response to ethanol may be highly variable, as like as humans [6], because of the intra-individual variability in detoxifying enzymes and non-linear BK channels 2 function [7,8]; its pharmacokinetics is complex, it does not depend on mouse strain and administration route, it has a dose-dependent linear increase in alcohol concentration in the plasma and brain and non linear or parabolic increase in the area under ethanol pharmacokinetic curve in tissues [9]. In the experimental conditions described above, it is difficult to assess if ethanol might exert a significant effect on pharmacokinetics of other drugs such as ergot alkaloids contained in *Gelsemium* plant extracts or buspirone, but what is well known is that ethanol possesses a significant influence on plasma pharmacokinetics of drugs, in a general way [10]. Furthermore, the effects of ethanol are often biphasic (stimulatory/inhibitory) as like as low doses of a plant extract [11], so rendering more complex any possible interpretation of the assay [12,13]. The association of ethanol with a different drug might change dramatically the fashion by which the drug operates in the behavioral test and a molecular or cellular comparison with the same molecule diluted into water [2,14] should not have been made, unless considering the introduction of a set of controls without ethanol. So, I wondered: why to use ethanol if homeopathic remedies use lactose globuli? Other concerns are the choice for behavioral tests.

Within this experimental condition open field test (OFT) and light-dark box test (LDT) were unable to discriminate sedation or anxiety by evaluating locomotor or exploratory activity by alone, due to ethanol interference. *Gelsemium sempervirens* Ait. alcoholic extract contains many other ergot alkaloids besides gelsemine, most of which exert many depressant and sedative effects [15,16]. Several reports dealing with herbal extracts in animal anxiety models are limited to the simplest standardized behavioral tests, which are indicated to measure locomotion and exploratory tendency as main parameters of a non-anxious behavior: in this context a decrease in these two parameters might be associated with other hallmarks, such as sedation or depression, then demonstrating that the complex mixture of compounds contained in the alcoholic plant extract may show many different pharmacological effects. Furthermore, when low doses of a plant-derived compound are used, hormetic effects may arise. Hormetic mechanisms have been described by using a broad panel of behavioral tests; the analysis revealed that hormetic-like biphasic dose-response were commonly observed across all screening tests [11]. These issues normally hamper a clear description of the anxiety-like behavior in tested animals, especially if environmental conditions are considered [17]. For example, dark box in LDT may be felt by mice as an aversive environment, so forcing the animal in spending more time in the lit arena and the lit area, if has the same light exposure of the whole environment, might do not elicit any aversive stimulus [4,18,19]. So, which is anxiety in laboratory rodents? Is the term anxiety interchangeable with fear, stress, panic or danger sensitivity? In animals, fear is an adaptive response that has evolved to provide protection from potential harmful environments, and fear-related behaviors in mice have long been investigated as potential models of anxiety disorders [20]. When fear is disproportionate in facing the harmful situation, it can lead to an anxiety disorder [21]. In laboratory animals, such as mice or rats, fear may be acquired when a neutral conditioned stimulus is paired with an aversive unconditioned stimulus and, usually, after several such pairings, the subjects is able to learn that the conditioned stimulus elicits several fear responses: in this circumstance, anxiety may arise [21]. This possibility occurs when the same operator makes serial injections and performs behavioral tests [4]. Research about the extinction of Pavlovian fear responses is yielding important information about the neural substrates of anxiety disorders, such as phobias and post-traumatic stress disorder (PTSD), even in humans. An advantage of the fear extinction model is that comparison of animal studies should suggest a considerable similarity between the neural structures which are involved in extinction in rodents and in humans. These studies allow to understand the neural mechanisms underlying behavioral interventions that suppress fear, including exposure therapy in anxiety disorders [22]. Fear and anxiety appear, therefore, as two different and strictly related paradigms in neuroscience. In laboratory, several behavioral tests are available to

*Corresponding author: Salvatore Chirumbolo, Department of Medicine-Section D, Ospedale Civile Maggiore-Lato Mameli-Ospedale Geriatrico, Italy, Tel: 390458128456; E-mail: salvatore.chirumbolo@uniir.it

Received November 01, 2011; Accepted November 16, 2011; Published November 17, 2011


Copyright: © 2011 Chirumbolo S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ascertain if the researcher is investigating a fear extinction mechanism, an anxiety disorder or an extinction of both, due to a pharmacological treatment. One good test is elevated plus-maze. Fear can be measured as a decreased percentage of time spent on open-arm exploration in the elevated plus-maze and can be potentiated by prior inescapable stress exposure, although not by escapable stress. In this case, the application of fear potentiated plus-maze behavior has several advantages as compared to more traditional animal models of anxiety, such as LD'T or OFT [4]. The traditional, elevated plus-maze is able to measure innate fear of open spaces but a fear-potentiated plus-maze behavior should reflect an enhanced anxiety state, called as allostatic state. This typical “state of anxiety” can be defined as an unpleasant emotional arousal in face of threatening demands or dangers [23]. Actually, a cognitive appraisal of threat is a prerequisite for the experience of this type of emotion. The fear-potentiated plus-maze behavior is sensitive to proven/putative anxiolytics and anxiogenics which act via mechanisms related to the benzodiazepine-gamma-aminobutyric acid receptor, but it is also sensitive to corticotropin-releasing receptor antagonists and glucocorticoid receptor antagonists and serotonin receptor agonists/antagonists complex [23]. In this strategy, neural mechanisms involved in contextual fear conditioning, fear potentiation and state anxiety can be studied, so rendering fear-potentiated plus-maze behavior a valuable measure in the understanding of neural mechanisms involved in the development of anxiety disorders and in the search for novel anxiolytics [23-25]. This assumption would like to suggest to better evaluate different behavioral tests in investigating anxiety-like models in animals, attempting to elicit biases at the lowest frequency possible, evaluate different behavioral tests in investigating anxiety-like models in the development of anxiety disorders and in the search for novel anxiolytics [23-25]. This assumption would like to suggest to better evaluate different behavioral tests in investigating anxiety-like models in animals, attempting to elicit biases at the lowest frequency possible, not to create a possible “integrate behavioral assay”. For the many reasons previously indicated, the interpretation of behavioral tests includes many tricky issues [2]. Statements and comments about the possible effectiveness of low concentrated alkaloids from alcoholic plant extracts have to be reappraised and evaluated at the light of bias analysis [26]. Anxiety-like models in laboratory animals such as rodents contain many unresolved and puzzling aspects that merit to be explained by using increasingly sophisticated approaches, aiming at not lapsing into easy conclusions.

References